Pharma Mar revenue and financials
In the fiscal year ended December 2025, Pharma Mar reported revenue of €221.39M (+26.61% year over year). Net income was €74.99M, a net margin of 33.9%.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +26.61%
- 2025 vs 2024
- Net income growth
- +187.03%
- 2025 vs 2024
- Net margin
- 33.9%
- 2024: 14.9%
How Pharma Mar is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue fell 3.9% a year on average over the last 5 years
Compound annual growth rate: from €269.96M in 2020 to €221.39M in 2025.
Operating margin rose from 21.4% to 27.4%
Operating income over revenue, 2022 → 2025: 6.0 percentage points.
Less cash than profit: free cash flow equal to 9% of net income
Totals for fiscal years 2023–2025: free cash flow €9.43M, net income €102.25M.
Shares outstanding down 4.8% in 5 years
Average diluted shares, 2020 → 2025: with fewer shares, each one represents a larger stake in the company.
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 221 | 175 | 158 | 196 | 230 | 270 | 85.8 | 109 | 159 | 181 |
| Cost of revenue | 12.3 | 8.2 | 9.6 | 13.6 | 16.4 | 13.7 | 5.2 | 4.9 | 34.9 | 44.0 |
| Gross profit | 209 | 167 | 149 | 183 | 213 | 256 | 80.6 | 104 | 124 | 137 |
| Selling, general and administrative | 59.4 | 47.2 | 41.8 | 43.2 | 39.7 | 36.0 | 37.8 | 38.9 | 57.6 | 68.0 |
| Research and development | 95.2 | 104 | 99.3 | 83.4 | 72.2 | 53.8 | 50.6 | 73.8 | 78.5 | 78.4 |
| Operating income | 60.7 | 6.5 | -3.8 | 42.1 | 92.4 | 157 | -17.5 | -16.0 | -19.5 | -18.7 |
| EBIT | 60.7 | 6.5 | -3.8 | 42.1 | 92.4 | 157 | -17.5 | -16.0 | -19.5 | -18.7 |
| EBITDA | 66.5 | 10.1 | -1.1 | 44.9 | 95.0 | 159 | -15.2 | -13.4 | -16.2 | -15.3 |
| Interest expense | 2.5 | 2.5 | 2.4 | 2.4 | 3.4 | 3.1 | 3.9 | 4.1 | 5.1 | 5.2 |
| Pre-tax income | 59.7 | 12.0 | -3.6 | 43.8 | 95.1 | 146 | -21.7 | -20.0 | -24.7 | -24.7 |
| Income tax | -15.3 | -14.1 | -4.8 | -5.6 | 2.3 | 8.3 | -12.5 | -2.9 | 3.5 | -0.6 |
| Net income | 75.0 | 26.1 | 1.1 | 49.4 | 92.9 | 137 | -11.4 | -5.5 | -26.7 | -24.1 |
| Net income to common shareholders | 75.0 | 26.1 | 1.1 | 49.4 | 92.9 | 137 | -9.2 | -17.1 | -28.2 | -24.1 |
| Basic EPS | 4.30 | 1.49 | 0.06 | 2.73 | 5.14 | 7.50 | -0.50 | -0.93 | -1.53 | -1.31 |
| Diluted EPS | 4.30 | 1.49 | 0.06 | 2.73 | 5.13 | 7.49 | -0.50 | -0.93 | -1.54 | -1.32 |
| Average shares (basic) | 17.4 | 17.5 | 17.9 | 18.1 | 18.1 | 18.3 | 18.4 | 18.4 | 18.4 | 18.4 |
| Average shares (diluted) | 17.5 | 17.6 | 17.9 | 18.1 | 18.1 | 18.3 | 18.5 | 18.4 | 18.4 | 18.4 |
| Dividend per share | 1.00 | 0.80 | 0.65 | 0.65 | 0.65 | 0.60 | 0.48 | — | — | — |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 54.4 | 49.6 | 42.9 | 90.5 | 35.7 | 56.4 | 38.9 | 48.4 | 45.7 | 42.9 | 38.0 | 40.5 |
| Cost of revenue | 3.7 | 4.7 | 3.7 | 3.8 | 2.3 | 2.8 | 3.4 | 1.3 | 2.0 | 3.1 | 1.8 | 2.5 |
| Gross profit | 50.7 | 44.9 | 39.2 | 86.7 | 33.4 | 53.6 | 35.5 | 47.0 | 43.6 | 39.8 | 36.2 | 38.1 |
| Selling, general and administrative | 15.5 | 17.1 | 15.3 | 17.3 | 6.6 | 14.7 | 13.7 | 13.2 | 10.7 | 19.4 | 11.0 | 11.4 |
| Research and development | 24.9 | 26.4 | 20.9 | 25.6 | 22.1 | 26.2 | 21.3 | 27.5 | 24.7 | 24.1 | 27.2 | 29.0 |
| Operating income | 7.7 | -1.4 | 0.6 | 43.6 | -4.0 | 24.2 | -3.1 | 4.9 | 5.5 | 0.4 | -4.3 | -5.1 |
| EBIT | 7.7 | -1.4 | 0.6 | 43.6 | -4.0 | 24.2 | -3.1 | 4.9 | 5.5 | 0.4 | -4.3 | -5.1 |
| EBITDA | 9.8 | 0.7 | 2.7 | 45.6 | -1.9 | 26.1 | -1.1 | 7.0 | 7.0 | 1.9 | -2.8 | -4.4 |
| Interest expense | — | — | — | 0.7 | 0.1 | 0.8 | 0.8 | 2.5 | 1.6 | — | — | 2.4 |
| Pre-tax income | 8.1 | -1.0 | 1.6 | 44.3 | -4.1 | 23.4 | -3.9 | 9.5 | 3.9 | 1.3 | -2.8 | -6.5 |
| Income tax | -0.0 | -0.0 | 0.1 | -15.4 | 0.0 | -0.0 | 0.0 | -9.1 | -0.0 | 0.1 | -5.1 | 0.3 |
| Net income | 8.1 | -1.0 | 1.5 | 59.7 | -4.1 | 23.4 | -3.9 | 18.7 | 3.9 | 1.2 | 2.3 | -6.8 |
| Net income to common shareholders | 8.1 | -1.0 | 1.5 | 59.7 | -4.1 | 23.4 | -3.9 | 18.7 | 3.9 | 1.2 | 2.3 | -6.8 |
| Basic EPS | 0.47 | -0.06 | 0.09 | 3.44 | — | 1.34 | -0.23 | 1.06 | — | 0.07 | — | -0.39 |
| Diluted EPS | 0.47 | -0.06 | 0.09 | 3.44 | — | 1.34 | -0.23 | 1.06 | — | 0.07 | — | -0.39 |
| Average shares (basic) | 17.3 | 17.3 | 17.3 | 17.4 | — | 17.4 | 17.3 | 17.6 | — | 17.5 | — | 17.6 |
| Average shares (diluted) | 17.3 | 17.3 | 17.3 | 17.4 | — | 17.4 | 17.3 | 17.6 | — | 17.5 | — | 17.6 |
| Dividend per share | — | — | — | 1.00 | — | — | — | 0.80 | — | — | — | 0.65 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 395 | 350 | 341 | 393 | 368 | 330 | 125 | 158 | 188 | 221 |
| Current assets | 283 | 250 | 253 | 275 | 295 | 246 | 50.0 | 75.1 | 93.2 | 121 |
| Cash and equivalents | 17.8 | 63.2 | 60.0 | 150 | 113 | 96.2 | 17.6 | 22.7 | 24.1 | 14.3 |
| Short-term investments | 149 | 91.3 | 103 | 32.6 | 88.5 | 99.3 | 3.3 | 4.1 | 7.7 | 18.1 |
| Receivables | 39.4 | 34.7 | 27.6 | 29.3 | 50.9 | 24.1 | 11.5 | 23.5 | 31.4 | 62.6 |
| Inventory | 50.6 | 50.9 | 39.3 | 27.7 | 10.5 | 11.9 | 8.9 | 20.6 | 23.9 | 22.2 |
| Net property, plant and equipment | 60.1 | 57.8 | 34.5 | 33.2 | 26.9 | 24.7 | 25.6 | 25.5 | 30.6 | 29.0 |
| Goodwill | — | — | — | — | — | — | — | 2.5 | 2.5 | 2.5 |
| Other intangible assets | 1.4 | 1.0 | 1.2 | 1.2 | 1.1 | 1.0 | 0.9 | 11.1 | 9.2 | 11.3 |
| Long-term investments | 0.6 | 2.5 | 6.1 | 49.4 | 10.7 | 21.0 | 1.0 | 0.9 | 1.0 | 1.1 |
| Current liabilities | 93.9 | 82.7 | 95.9 | 97.3 | 86.3 | 94.9 | 60.4 | 72.4 | 83.1 | 87.2 |
| Accounts payable | 40.9 | 38.8 | 29.2 | 27.5 | 26.9 | 21.0 | 16.5 | 31.2 | 35.8 | 36.7 |
| Long-term debt | 35.6 | 39.9 | 27.0 | 25.9 | 33.4 | 37.7 | 53.1 | 64.9 | 73.6 | 67.6 |
| Total debt | 44.6 | 46.4 | 37.2 | 38.1 | 45.5 | 51.9 | 72.3 | 78.4 | 87.8 | 83.6 |
| Total liabilities | 143 | 141 | 147 | 170 | 190 | 228 | 117 | 140 | 165 | 173 |
| Total equity (incl. minority) | 252 | 208 | 193 | 223 | 178 | 103 | 7.5 | 17.5 | 23.0 | 48.5 |
| Retained earnings | 234 | 168 | 142 | 157 | 121 | 41.9 | -69.6 | -58.8 | -51.1 | -24.7 |
| Minority interest | — | — | — | — | — | — | -3.9 | -3.9 | -3.9 | -3.9 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 408 | 394 | 385 | 395 | 342 | 348 | 333 | 350 | 333 | 317 | 334 | 341 |
| Current assets | 296 | 281 | 273 | 283 | 243 | 249 | 236 | 250 | 238 | 224 | 241 | 253 |
| Cash and equivalents | 44.6 | 19.3 | 48.9 | 17.8 | 49.7 | 21.6 | 60.3 | 63.2 | 34.8 | 19.3 | 35.7 | 60.0 |
| Short-term investments | 132 | 150 | 119 | 149 | 96.9 | 106 | 80.6 | 91.3 | 110 | 116 | 124 | 103 |
| Receivables | 53.7 | 47.9 | 40.0 | 39.4 | 33.5 | 59.8 | 36.8 | 34.7 | 33.7 | 30.0 | 26.9 | 27.6 |
| Inventory | 53.1 | 49.5 | 53.1 | 50.6 | 53.0 | 49.5 | 50.5 | 50.9 | 47.8 | 47.2 | 43.5 | 39.3 |
| Net property, plant and equipment | 59.9 | 60.0 | 59.7 | 60.1 | 57.0 | 57.7 | 58.3 | 57.8 | 57.7 | 54.7 | 53.7 | 34.5 |
| Other intangible assets | 4.0 | 4.0 | 3.8 | 1.4 | 1.2 | 1.1 | 1.0 | 1.0 | 1.2 | 1.4 | 1.7 | 1.2 |
| Long-term investments | 0.6 | 0.6 | 0.6 | 0.6 | 0.8 | 0.8 | 1.4 | 2.5 | 3.8 | 4.5 | 4.7 | 6.1 |
| Current liabilities | 125 | 98.4 | 89.2 | 93.9 | 88.9 | 87.8 | 79.5 | 82.7 | 89.4 | 87.9 | 92.3 | 95.9 |
| Accounts payable | 50.6 | 38.9 | 43.8 | 40.9 | 43.8 | 37.1 | 42.0 | 38.8 | 35.2 | 32.8 | 34.6 | 29.2 |
| Long-term debt | 34.6 | 32.1 | 33.2 | 35.6 | 36.6 | 37.6 | 38.6 | 39.9 | 41.0 | 26.0 | 25.9 | 27.0 |
| Total debt | 70.1 | 41.8 | 47.5 | 44.6 | 50.3 | 46.4 | 46.9 | 46.4 | 53.5 | 34.5 | 35.0 | — |
| Total liabilities | 171 | 143 | 136 | 143 | 144 | 147 | 136 | 141 | 151 | 136 | 141 | 147 |
| Total equity (incl. minority) | 237 | 251 | 250 | 252 | 198 | 202 | 197 | 208 | 182 | 181 | 193 | 193 |
| Retained earnings | 248 | 240 | 235 | 234 | 173 | 188 | 165 | 168 | 148 | 144 | 144 | 142 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 53.1 | 6.0 | -13.4 | 38.3 | 25.7 | 279 | -24.2 | -16.8 | -1.5 | -8.4 |
| Depreciation and amortization | 7.7 | 5.7 | 4.7 | 4.9 | 4.6 | 4.3 | 4.3 | 2.6 | 3.4 | 3.4 |
| Capital expenditure | -6.5 | -15.0 | -14.8 | -8.9 | -7.8 | -3.0 | -4.0 | -1.9 | -3.5 | -6.1 |
| Investing cash flow | -60.8 | 1.0 | -43.0 | 10.9 | 18.5 | -119 | 32.1 | 22.7 | 6.0 | 13.8 |
| Financing cash flow | -36.5 | -5.4 | -32.1 | -13.4 | -27.4 | -73.8 | -13.0 | -7.3 | 5.3 | 1.3 |
| Dividends paid | -13.9 | -11.4 | -11.7 | -11.8 | -10.9 | -8.8 | — | — | — | — |
| Share repurchases | -34.1 | -18.6 | -37.9 | -50.2 | -40.7 | -63.7 | -7.5 | -3.4 | -6.2 | -4.2 |
| Debt issued | 1.3 | 15.4 | 7.2 | 1.5 | 5.8 | 0.8 | 4.8 | 10.2 | 21.1 | 20.1 |
| Debt repaid | -5.7 | -9.6 | -8.4 | -10.2 | -15.3 | -32.4 | -18.8 | -16.8 | -16.7 | -18.2 |
| Effect of exchange rates | -1.2 | 1.5 | -1.2 | 0.6 | 0.4 | -7.5 | — | — | — | — |
| Net change in cash | -45.4 | 3.2 | -89.8 | 36.5 | 17.1 | 78.6 | -5.1 | -1.3 | 9.8 | 6.7 |
| Free cash flow | 46.7 | -9.0 | -28.3 | 29.5 | 17.9 | — | — | — | — | — |
| Levered free cash flow | 22.9 | -20.2 | -12.6 | 33.1 | 4.8 | 128 | -4.7 | -7.0 | 12.1 | -18.3 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 7.3 | 3.4 | 8.6 | 33.6 | 16.7 | 9.1 | -6.3 | 1.7 | 4.2 | -9.2 | 9.3 | -2.7 |
| Depreciation and amortization | 2.1 | 2.1 | 2.1 | 1.7 | 2.0 | 2.0 | 2.0 | 1.1 | 1.5 | 1.6 | 1.5 | 0.5 |
| Capital expenditure | -1.4 | -2.3 | -1.3 | -3.3 | -1.2 | -1.4 | -0.5 | -1.4 | -3.7 | -2.6 | -7.3 | -4.6 |
| Investing cash flow | 16.8 | -32.4 | 29.0 | -58.2 | 12.9 | -26.8 | 11.3 | 20.4 | 0.9 | 6.7 | -27.0 | 1.7 |
| Financing cash flow | 1.2 | -0.1 | -7.0 | -7.6 | -2.0 | -20.0 | -6.8 | 4.2 | 10.8 | -13.6 | -6.7 | -6.3 |
| Dividends paid | -17.3 | — | — | 0.0 | 0.0 | -13.9 | — | 0.0 | 0.0 | -11.4 | — | — |
| Share repurchases | -4.7 | -2.3 | — | -21.7 | -2.0 | -5.5 | -7.7 | -8.5 | -3.2 | -1.9 | -5.1 | -6.0 |
| Debt issued | 18.4 | — | — | 1.3 | -2.3 | -2.1 | 2.1 | 0.0 | 15.0 | 0.4 | — | 2.3 |
| Debt repaid | 4.8 | -2.1 | -2.7 | -3.1 | 0.2 | 1.5 | -1.9 | -3.5 | -1.0 | -1.4 | -3.6 | -2.6 |
| Effect of exchange rates | 0.0 | -0.4 | 0.5 | 0.3 | 0.6 | -1.0 | -1.2 | 2.1 | -0.5 | -0.3 | 0.1 | -1.2 |
| Net change in cash | 25.2 | -29.5 | 31.0 | -31.9 | 28.1 | -38.7 | -2.9 | 28.4 | 15.5 | -16.4 | -24.3 | -10.0 |
| Free cash flow | 5.9 | 1.1 | 7.2 | 30.2 | 15.5 | 7.7 | -6.8 | 0.3 | 0.5 | -11.8 | 2.0 | -7.2 |
| Levered free cash flow | 3.7 | 2.4 | 6.7 | 7.4 | 24.3 | -3.5 | -5.4 | -5.9 | -2.0 | -11.7 | -1.6 | -3.0 |
Financial statements of similar companies
Companies in the group: same industry, similar size
